Aspreva is currently evaluating CellCept for the treatment of pemphigus vulgaris (PV) in a global phase III study. The randomized, double-blind, placebo-controlled comparison study is investigating the efficacy
The company said that its global clinical operations (GCO) unit will establish this global set of standards, policies and practices, and build a management system that will oversee
Under the agreement, Human Genome Sciences (HGS) and Novartis will co-commercialize Albuferon in the US, and will share costs and profits equally. Outside of the US, Novartis will
In addition, Gilead has entered into long-term agreements with Degussa for the supply of raw materials and the manufacture of certain active pharmaceutical ingredients (API) for Gilead products.
Tarceva is currently approved as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) patients who have failed prior chemotherapy, and in combination with the
Orphan drug status, given to drugs intended to treat diseases afflicting less than 200,000 people in the US, will entitle Xechem to various incentives, including the waiving of
This trial is being sponsored by the US National Cancer Institute (NCI) under an agreement with CuraGen and will be conducted at multiple sites in the US. Up
As patients with advanced cancer may often have limited function of the liver and/or kidneys, it is important to understand how these impairments affect how a drug is
The study found that patients receiving any dose of Hi-8 MEL who developed a CD8+ response specific to melan-A (one of seven melanoma-specific epitopes used in the Hi-8
In the phase III, open-label study, 430 patients with metastatic colorectal cancer (mCRC) were randomized to receive first-line treatment with one of three Campto-based regimens: Folfiri, mIFL or
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.